Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model

Kallio-Kujala, Ira Janika; Bennett, Rachel C.; Raekallio, Marja; Yatkin, Emrah; Meierjohann, Axel; Savontaus, Eriika; Scheinin, Mika; Spillmann, Thomas; Vainio, Outi

doi:10.1016/j.tvjl.2018.09.012

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concomitant use of MK-467 in dogs treated with dexmedetomidine averted the major alterations in plasma concentrations of glucose, insulin, non-esterified fatty acid and lactate (Restitutti et al, 2012). A review by Kallio-Kujala et al (2018b) also illuminates the effects of dexmedetomidine and MK-467 combination in canine glibenclamide-induced hypoglycaemia model to predict its safety in hypoglycaemic dogs undergoing sedation. They opined that the potentiation of glibenclamide-evoked hypoglycaemia was not observed when the MK-467 was co-administered with dexmedetomidine and thereby stated that the co-administration of MK-467 and dexmedetomidine appears to be safe in the glibenclamide induced canine hypoglycaemia model.…”

Section: Effect On Plasma Glucose Insulin Non-esterified Fatty Acidmentioning

confidence: 99%

Various Systemic Effects of MK-467, A Peripherally Acting α2-adrenoceptor Antagonist in Different Animal Species: An Overview

Akash

Hoque

Amarpal

2020

View full text Add to dashboard Cite

Most commonly used α2-adrenoceptor agonist shows adverse cardiovascular effects during anaesthesia. They mainly depress the cardiovascular system by provoking vasoconstriction followed by bradycardia. Although α2-adrenoceptor antagonist like atipamezole can reverse these effects along with that they also reverse the sedation and nociception. Concomitant administration of peripherally acting α2-adrenoceptor antagonist MK-467 can reverse the adverse cardiovascular effect of α2-adrenoceptor agonists without affecting the sedation and nociception. MK-467 has been successfully used in different animals like dogs, cats, sheep, horses along with different α2-adrenoceptor agonist drugs. This review aims to summarize the effects of MK-467 on sedation, cardiopulmonary system, the minimum alveolar concentration of different inhalant anaesthetics, plasma drug concentration, plasma glucose and insulin in different animals.

show abstract

Section: Effect On Plasma Glucose Insulin Non-esterified Fatty Acidmentioning

confidence: 99%

Various Systemic Effects of MK-467, A Peripherally Acting α2-adrenoceptor Antagonist in Different Animal Species: An Overview

Akash

Hoque

Amarpal

2020

View full text Add to dashboard Cite

show abstract

“…Another important block of research is the study of the combined effect of α2-AM with drugs of other pharmacological groups [55], which to a greater extent potentiate the analgesic or anesthetic effect of each other. These studies are naturally associated with clinical trials with various groups of people [56,57,58].…”

Section: The Analysis Of Trends and Directions Of Research Of α2-am-amentioning

confidence: 99%

“…Separate studies are devoted to the research of combined application of agonists and antagonists of α2-AM [55]. In these publications, the authors set themselves a goal to stop possible side and undesirable effects, as well as to achieve more controlled sedation.…”

Section: The Analysis Of Trends and Directions Of Research Of α2-am-amentioning

confidence: 99%

Tendencies and perspectives of central alpha2-adrenomimetic application in medicobiological research

et al. 2019

View full text Add to dashboard Cite

The pharmacodynamic effects of the administration of 2-adrenergic agonists both in a monovariant and in combination with drugs of other pharmacological groups are considered. Based on analysis of safety nonclinical studies the characteristics of main physiological effects of 2-adrenergic receptors as well as physiological effects of 2-agonists on various organs and systems are presented. For the determination of tendencies and directions in research of central 2-AM (dexmedetomidine) the analysis of bibliographical data, accumulated and extracted from Medline database with 5 year time-filter (VOSviewer, 1.6.11 version) has been carried out. For the further research of central 2-adrenomimetics and their application in clinical practice the following perspective directions have been determined: the study of effects and mechanisms of cytoprotectant and antioxidant action, the study of the use of drugs in a monovariant and in combinations for the development of analgesic drugs, anesthesia and development of combined formulations with a delayed release of antagonists designed to mitigate side effects.

show abstract

“…Bouillon et al reported that a single large dose (10 mcg/kg) of dexmedetomidine doubled median blood glucose concentration in healthy cats from 109.01 mg/dL to 208.11 and 216.22 mg/dL (6.05 mmol/L to 11.55 and 12 mmol/L) at 1 and 2 h, respectively, with significant reduction in serum insulin concentration ( 6 ). Dexmedetomidine has also demonstrated efficacy in the reduction of serum insulin concentration secondary to the administration of glibenclamide ( 7 ). Glibenclamide is classified as a sulfonylurea, which acts by stimulating insulin release from pancreatic beta cells.…”

Section: Introductionmentioning

confidence: 99%

“…Glibenclamide and other sulfonylureas are utilized in the treatment of non-insulin dependent diabetic patients. Dexmedetomidine administered at a dose of 5 mcg/kg did not alter serum glucose concentration markedly but significantly reduced serum insulin concentration in glibenclamide-induced hypoglycemia models ( 7 ). Burton et al demonstrated the administration of medetomidine at doses of 10 and 20 mcg/kg doses transiently reduced serum insulin concentration with little effect on serum glucose concentrations in six healthy beagles ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Case report: Low dose dexmedetomidine infusion for the management of hypoglycemia in a dog with an insulinoma

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo describe the use of a low dose dexmedetomidine infusion as preoperative treatment for hypoglycemia secondary to a functional pancreatic tumor in a dog.Case summaryAn 8.7-year-old castrated male Hungarian Vizsla presented for further evaluation of persistent hypoglycemia after the referring veterinarian established a tentative diagnosis of insulinoma based on paired insulin and glucose measurements. Abdominal ultrasound and computed tomography demonstrated evidence of a pancreatic mass with possible hepatic metastases. Attempts to aspirate the lesions under ultrasound guidance were unsuccessful, and the dog was hospitalized overnight for planned surgical resection of the presumed pancreatic tumor and biopsy of the hepatic lesions the following day. In response to a progressive increase in patient anxiety and agitation trazodone was prescribed ~5 mg/kg orally every 8 h and gabapentin at ~7 mg/kg every 8 h. As the dog continued to remain anxious dexmedetomidine at a dose of 1 mcg/kg was administered intravenously immediately followed with an infusion of dexmedetomidine at 1 mcg/kg/h. The anxious behaviors were successfully controlled with minimal cardiovascular side effects. Serial blood glucose measurements obtained during this time demonstrated euglycemia. The dog remained euglycemic while receiving dexmedetomidine for the remainder of the pre-operative period and for duration of hospitalization following surgical resection and biopsy.New or unique information providedThis case report demonstrates a possible role for dexmedetomidine to counteract hypoglycemia in dogs with insulinomas.

show abstract

Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model

Cited by 7 publications

References 21 publications

Various Systemic Effects of MK-467, A Peripherally Acting α2-adrenoceptor Antagonist in Different Animal Species: An Overview

Various Systemic Effects of MK-467, A Peripherally Acting α2-adrenoceptor Antagonist in Different Animal Species: An Overview

Tendencies and perspectives of central alpha2-adrenomimetic application in medicobiological research

Case report: Low dose dexmedetomidine infusion for the management of hypoglycemia in a dog with an insulinoma

Contact Info

Product

Resources

About